PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2030-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the uptake of \[18F\]FTC-146 in healthy volunteers to that of individuals suffering from chronic pain with Spinal or Peripheral Nerve Origin.

Primary Objectives:

A) To quantify the bio-distribution of \[18F\] FTC-146 uptake in subjects with Spinal or Peripheral Nerve Origin pain and compare it with healthy controls.

B) To determine whether painful schwannomas can be differentiated from non-painful schwannomas based on imaging.

Secondary Objectives:

A) To assess the reproducibility of \[18F\]FTC-146 PET imaging within the same healthy volunteer subjects using Test-Retest analysis.

B) To investigate whether post-treatment \[18F\]FTC-146 uptake differs from pre-treatment uptake and correlate the imaging with subject reported pain level after treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Magnetic Stimulation for Facial Pain

NCT02633306

Trigeminal Nerve Injuries Post-herpetic Neuralgia Facial Pain +1 more

COMPLETED NA

Brain, Brainstem, and Spinal Cord fMRI

NCT02356315

Neck Pain Chronic Pain

COMPLETED

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

NCT03003715

Trigeminal Neuropathic Pain

COMPLETED NA

PET Imaging of Chronic Pain Syndromes

NCT03233594

Chronic Pain Syndrome

ACTIVE_NOT_RECRUITING

Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication

NCT00388414

Low Back Pain

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic pain represents a significant and widespread problem affecting approximately one-fifth person of the global population. As reported by the Institute of Medicine in 2011, chronic pain impacts 116 million American adults, surpassing the combined prevalence of heart disease, cancer, and diabetes. The economic burden associated with chronic pain is staggering, with an estimated annual expenditure of $635 billion on medical management and lost productivity1. Chronic pain can interfere with a person's daily life and lead to depression, insomnia and anxiety which can make the chronic pain worse. Chronic pain has many forms and appears across the body. For this study we will focus on chronic pain with spinal or peripheral nerve origin.

Chronic pain in the spinal cord or peripheral nerves can be caused by neuropathic pain, which occurs when the nervous system is damaged or malfunctions. Tumors, specifically schwannomas, are known to cause neuropathic chronic pain in subjects. The chronic pain can also be caused by nociceptive pain which is a type of pain that occurs when body tissue is damaged by physical or chemical agents, such as trauma, surgery, or chemical burns.

Pain is common and debilitating in people with schwannomatosis: Pain is the defining feature of most forms of schwannomatosis. While neurologic deficits (e.g., weakness) are relatively rare, pain is extremely common. Pain correlates with greater disability, and pain-related interference in daily activities correlates with poorer quality of life.

In patients with schwannomatosis, due to the presence of multiple tumors and frequent non-tumorigenic sources of pain, identifying the pain-generating tumor(s) can be difficult. This is particularly true since there does not seem to be any correlation between tumor size or active tumor growth and pain. Furthermore, even when pain can be localized to a specific nerve distribution, the nerve in question often will have multiple tumors along its course.

Current clinical methods for diagnosing and localizing pain generators are inadequate, highlighting the urgent need for more objective molecular assays capable of identifying sites of enhanced nociceptive activity. This will facilitate better diagnosis and targeted therapy for the patient. Additionally, the limited number availability of analgesic options for chronic and neuropathic pain patients, coupled with significant adverse effects, underscores the critical need for safer and better-tolerated analgesics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nerve Pain Neuropathic Pain Nociceptive Pain MIxed Pain (Nociceptive and Neuropathic)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

All enrolled subjects (Pain Patients and Healthy Volunteers) will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pain Patients With Spinal or Peripheral Nerve Origin

Individuals suffering from nerve pain that is of spinal or peripheral nerve origin and undergo a \[18F\]FTC-146 PET/MRI scan.

Group Type EXPERIMENTAL

[18F]FTC-146

Intervention Type DRUG

Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Healthy Volunteers

Individuals who do not have pain and undergo a \[18F\]FTC-146 PET/MRI scan.

Group Type EXPERIMENTAL

[18F]FTC-146

Intervention Type DRUG

Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]FTC-146

Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Volunteers

1\. At least 18 years old.
* Pain Subjects

1. At least 18 years old.
2. Chronic Pain is of Spinal or Peripheral Nerve Origin
3. Subject's Chronic pain lasting greater than 2 months.
4. Pain level of at least 4/10 on a 0-10 Comparative Pain Scale.

Exclusion Criteria

* Healthy Volunteers

1. Any chronic Pain
2. Use of pain medication.
3. MRI incompatibility.
4. Kidney problems.
5. Pregnant or nursing.
6. Non-English speaker.
7. Presence of vasculopathy or Raynaud's.
8. Inability to tolerate cessation of anticoagulant medication during the study.
* Pain Subjects

1. MRI incompatibility.
2. Kidney problems.
3. Pregnant or nursing.
4. Non-English speaker.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes